Citation

Ney LJ, Matthews A, Bruno R, Felmingham KL. Neurosci. Biobehav. Rev. 2018; 94: 302-320.

Affiliation

School of Psychological Sciences, University of Melbourne, Australia.

Copyright

(Copyright © 2018, Elsevier Publishing)

DOI

10.1016/j.neubiorev.2018.07.006

PMID

30017748

Abstract

The endocannabinoid system is an increasingly recognised pharmacological target for treating stress and anxiety disorders, including post-traumatic stress disorder (PTSD). Recent preclinical developments have implicated the endocannabinoid system in stress responses, emotional memories and fear extinction, all critical to PTSD aetiology. However, preclinical research in endocannabinoid biology has neglected the influential role of sex hormone differences on PTSD symptomology, which is particularly important given that PTSD is twice as common in women as in men. In this review, we compile and consider the evidence that the endocannabinoid system is influenced by ovarian hormones, with application to stress disorders such as PTSD. It is clear that therapeutic modulation of the endocannabinoid system needs to be approached with awareness of ovarian hormonal influences, and knowledge of these influences may enhance treatment outcomes for female PTSD populations.

Copyright © 2018. Published by Elsevier Ltd.

Language: en

Keywords

cannabinoids; cannabis; endocannabinoids; oestrogens; posttraumatic stress disorder; psychiatric disorders; sex differences; translational medical research; traumatic stress